Stay in touch!

Accrete-D3

The least expensive calcium + vitamin D3 brand offering a choice of swallowable and chewable tablets1,2

Non-adherence to osteoporosis therapy places a huge burden on healthcare systems; the cost/patient is six times higher than with diabetes medication.3 Flavour, texture, and pill burden can impact on adherence.4

Accrete is Indicated for the prevention and treatment of vitamin D and calcium deficiency in the elderly. Adjunct to specific osteoporosis treatment for patients at risk of vitamin D and calcium deficiency.5,6

Accrete Prescribing Information
img-9
img-10

Respecting patient preference is an important way to support treatment persistence.7

With Accrete-D3, patients at risk of calcium and vitamin D3 deficiency have a choice:

thumb

Twice-daily, film-coated, swallowable tablets5

thumb

OR…

thumb

Once-daily, orange-flavoured, chewable tablets6

thumb

The cost of either treatment option is just £2.95 for 30 days, this is equivalent to approximately £35.40 per year.

thumb

Provides savings of up to 39% compared with the market leading brand1,5,6,8,9*

During pregnancy, daily dose should not exceed 1500 mg calcium and 600 IU vitamin D. See SMPC for more information.

* Savings of up to 39% with Accrete-D3 One a Day (1000mg/880IU) chewable tablets at £2.95 for 30 tablets vs Adcal-D3 (600mg/400IU) twice daily chewable tablets at £4.82, this is an equivalent cost for 30 days treatment. Adcal-D3 (600mg/400IU) twice daily chewable tablets are listed at £8.99 for 112 tablets

Request Cost
Savings Report

Accrete is the least expensive calcium + vitamin D3 brand offering a choice of swallowable and chewable tablets.1

Please complete this form and a member of our team will contact you with specific cost-savings information for your locality.

Register for Cost Savings

Patient Guide download

Please register for an instant download of the Accrete patient guide for more information on the importance of a calcium-vitamin D treatment and tips on how to improve bone health alongside the treatment.

Register to download
shape-3
References
  1. DM+D. Available at: services.nhsbsa.nhs.uk/dmd-browser Accessed: December 2023.
  2. NHS List Price, Drug Tariff February 2023
  3. Cutler RL et al. BMJ Open 2018; 8(1): e016982.
  4. Shariff Z et al. Pharmaceutics 2020; 12(10): 905.
  5. Accrete D3 Film-Coated Tablets Summary of Product Characteristics: https://www.medicines.org.uk/emc/product/2766. Accessed: November 2023.
  1. Accrete D3 One a Day 1000 mg / 880 IU Chewable Tablets Summary of Product Characteristics: https://www.medicines.org.uk/emc/product/8506. Accessed: November 2023.
  2. Martin LR et al. Ther Clin Risk Manag 2005 Sep;1(3):189-99.
  3. HSCIC IQVIA RXA Unit Sales ending December 2022.
  4. Adcal-D3® Chewable Tablets. Summary of Product Characteristics: https://www.medicines.org.uk/emc/product/1356/smpc. Accessed: November 2023.
  5. Adcal-D3® is a registered trademark of Kyowa Kirin Services Ltd.
Information

For information on our products please visit EMC, https://www.medicines.org.uk/emc/ and search the product for a Summary of Product Characteristics

Adverse events should be reported. Reporting forms and information can be found at: www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Thornton and Ross Limited by emailing thorntonross@medinformation.co.uk or by calling 01484 848164

UK-MULT-130a(2)     |     Date of Preparation December 2023

footer-logo

Thornton & Ross is a member of the STADA Group © Copyright Thornton & Ross 2023